Morgan Stanley lifted their price target on shares of Veracyte from $37.00 to $47.00 and gave the company an “underweight” rating in a research report on Thursday, July 9th. UBS Group increased their price objective on shares of Veracyte from $48.00 to $52.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Wall Street Zen raised Veracyte from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Finally, Canaccord Genuity Group reduced their price objective on Veracyte from $60.00 to $50.00 and set a “hold” rating on the stock in a research note on Monday. Veracyte Price PerformanceVeracyte stock opened at $44.85 on Tuesday.